344-29-6 Usage
Description
2-AMINO-5-FLUORO-3-NITROBENZOTRIFLUORIDE is a chemical compound that belongs to the class of substituted benzotrifluorides. It is characterized by the presence of an amino group, a fluorine atom, and a nitro group attached to a benzene ring, with three trifluoromethyl groups attached to it. This unique structure makes it a valuable research intermediate in the development of various chemical and pharmaceutical applications.
Uses
Used in Research and Development:
2-AMINO-5-FLUORO-3-NITROBENZOTRIFLUORIDE is used as a research intermediate for the synthesis of various organic compounds and pharmaceuticals. Its unique structure allows for the development of new chemical entities with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-AMINO-5-FLUORO-3-NITROBENZOTRIFLUORIDE is used as a key intermediate in the synthesis of drug candidates. Its versatile chemical properties enable the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Chemical Industry:
2-AMINO-5-FLUORO-3-NITROBENZOTRIFLUORIDE is also used in the chemical industry for the production of various specialty chemicals, such as dyes, pigments, and agrochemicals. Its unique structure and reactivity make it a valuable building block for the synthesis of these compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 344-29-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,4 and 4 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 344-29:
(5*3)+(4*4)+(3*4)+(2*2)+(1*9)=56
56 % 10 = 6
So 344-29-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H4F4N2O2/c8-3-1-4(7(9,10)11)6(12)5(2-3)13(14)15/h1-2H,12H2
344-29-6Relevant articles and documents
Glycine receptor antagonists and the use thereof
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.